Bristol Myers Squibb (BMY) concluded the recent trading session at $56.81, signifying a -0.58% move from its prior day's close.

Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes and sells ...

Legacy Private Trust Co. lifted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.3% during the 4th quarter, ...

First Hawaiian Bank raised its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.5% during the 4th quarter, ...

Like a champion boxer on the ropes, Bristol-Myers Squibb (NYSE: BMY) finds itself in a challenging position. Specifically, ...

The stock market saw something incredible in 2024, with the “Magnificent 7” tech giants leading the charge and driving a huge ...

Schwab U.S. Dividend Equity ETF is a clear buy with a look at its top 10 holdings. Click here to why I rate SCHD a Buy.

Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...

IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline. The company (IGMS) had 198 ...

MitoRx Therapeutics strengthens its leadership with the appointments of Lubor Gaal as chief business officer and Stacey ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

Amid a roller-coaster end to 2024 for the stock market, dividend-paying stocks continued to lag the broader market. However, ...